Hims weight-loss and medication pricing: hims.com/weight-loss, hims.com/weight-loss/drug-pricing, hims.com/weight-loss/wegovy, hims.com/weight-loss/zepbound-vial, hims.com/weight-loss/zepbound-kwikpen Hims FAQ and cancellation policy: hims.com/weight-loss/faq and support.hims.com Noom Med pricing and program tiers: noom.com/med, noom.com/med/pricing, noom.com/med/glp-1rx, noom.com/med/microdose-glp1-rx, noom.com/blog/weight-management/noom-cost Noom refund and cancellation policy: noom.com/support HimsNovo Nordisk March 2026 partnership and HimsEli Lilly April 2026 expansion official press releases from both companies FDA approval of Foundayo (orforglipron) fda.gov, April 1, 2026 FDA approval of Wegovy HD 7.2mg fda.gov, March 19, 2026 FDA proposed rule excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list fda.gov April 30, 2026
Its proven to ease symptoms of nerve damage and lower the risk of diabetic retinopathy (eye damage) that can occur with uncontrolled diabetes ( Its believed that this effect is due to the powerful antioxidant properties of alpha-lipoic acid ( Though alpha-lipoic acid has been shown to aid blood sugar control, its not considered a complete treatment for diabetes
The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke
The MHRA has issued warnings about the risks of obtaining unlicensed injectable peptides including GLP-1 receptor agonists from unregulated online sources, citing concerns about uncertain purity and potency, absence of validated stability data, risk of microbial contamination in preparations not manufactured under Good Manufacturing Practice (GMP) conditions, and the potential for mislabelling or adulteration
